At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
IBI308 +1 morebiological
Likely dose
IBI308 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)
In Brief
A Phase 2 clinical trial evaluating IBI308 and paclitaxel/ irinotecan for Esophageal Squamous Cell Carcinoma. Completed, enrolled 190 participants across 1 site.
Detailed Summary
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedApr 14, 2017
Enrollment StartMay 10, 2017
Primary CompletionOct 2, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.2 years ago
Interventions
IBI308biological
IBI308 200mg Intravenous drip every three weeks；
paclitaxel/ irinotecandrug
paclitaxel 175mg/㎡ Intravenous drip every three weeks or irinotecan 180mg/㎡ Intravenous drip every two weeks